Chandan Healthcare Ltd H1 FY26 – ₹137.5 Cr Revenue, ₹15.6 Cr PAT, 46% Profit Growth: UP–Uttarakhand Ka Diagnostic Don
1. At a Glance – “X-Ray Se Zyada Clear Numbers”
Chandan Healthcare Ltd is currently strutting around the SME market with the confidence of a radiologist who just spotted a hairline fracture on the first glance. Market cap sits around ₹712 crore, stock price chilling near ₹291, and the company has delivered a spicy 29% return in just three months—which is faster than most pathology reports in government hospitals. The latest half-yearly results show ₹137.49 crore revenue and ₹15.6 crore PAT, translating into a very respectable 19.5% operating margin and 46.6% YoY profit growth. ROE is hovering at 27%, ROCE close to 29%, and debt-to-equity is a manageable 0.48, meaning the balance sheet is not gasping for oxygen yet. P/E of ~26x places it cheaper than the fancy pan-India diagnostic chains but costlier than your local mohalla lab. In short, Chandan is behaving like that Tier-2 city topper who suddenly cracks an all-India rank and makes everyone nervous. Question is—can it sustain the pressure, or is this just IPO ka josh?
2. Introduction – Diagnostic Dhandha, Desi Style
Diagnostics in India is one of those businesses that looks boring until you realise it prints money with the consistency of a government exam form fee. Chandan Healthcare Ltd, incorporated back in 2003, has been quietly building a diagnostic empire across Uttar Pradesh and Uttarakhand—two states where population density is high, healthcare penetration is uneven, and demand for pathology tests is practically recession-proof.
Unlike the big boys who shout “premium brand” and charge ₹3,000 for a vitamin test, Chandan plays the volume game. More labs, more collection centres, faster turnaround, and prices that don’t give patients mild cardiac arrest. Over the years, it has built a dense network of 1 flagship lab, 9 central labs, 27 satellite centres, and a massive 351 collection centres. This is not expansion; this is colonisation.
The company recently listed in February 2025, raised ₹107 crore through IPO, and immediately started behaving like a kid who got pocket money after boards—new centres, acquisitions, partnerships, and PPP projects. But behind the noise, the numbers matter. And thankfully, Chandan’s numbers are not just cosmetic radiology images; they have depth.
So let’s dissect this company like a CT scan—layer by layer, contrast enhanced, no radiation spared.
3. Business Model – WTF Do They Even Do?
At its core, Chandan Healthcare does one simple thing: tests. Blood, urine, scans, MRIs, CTs—if doctors can prescribe it, Chandan wants to process it.
The company operates on a hub-and-spoke model. Think of it as Swiggy for blood samples. Collection centres (spokes) gather samples from patients, clinics, and hospitals, and then ship them to central laboratories (hubs) where the actual testing happens. This improves utilisation, reduces duplication of expensive machines, and keeps margins healthier than a sugar-free diabetic patient.
The service mix is broad:
Pathology: 1,496 tests ranging from basic CBC to advanced diagnostics.
Radiology: 545 services including X-ray, ultrasound, CT, and MRI, supported by 11 CT scanners and 4 MRI machines.
Preventive healthcare: Wellness packages, corporate health check-ups, home sample collection.
Pharmacy & FMCG via subsidiary Chandan Pharmacy Ltd—because why stop at diagnosis when you can also sell masks and tablets?
The client mix is equally desi:
B2B (62%) – hospitals, clinics, corporates.
B2G (26%) – government health schemes and PPP contracts.
B2C (balance) – walk-in patients and home collections.
The beauty of this model? Once volumes scale, incremental margins expand. Machines don’t complain about overtime. Logistics costs stabilise. And doctors keep prescribing tests like it’s free real estate. But here’s the catch—execution needs to be tight. Any delay, any quality issue, and reputation goes for a blood test of its own. Are they handling it well? Numbers suggest yes… for now.
4. Financials Overview – Half-Yearly Numbers That Don’t Need Re-Testing
Half-Yearly Comparison Table (₹ in crore, EPS in ₹)
Source table
Metric
Latest H1 FY26 (Sep 2025)
H1 FY25
Previous Half (Mar 2025)
YoY %
HoH %
Revenue
136
110
120
23.6%
13.3%
EBITDA
28
20
21
40.0%
33.3%
PAT
17
11
12
54.5%
41.7%
EPS
6.38
5.32
4.72
19.9%
35.2%
Annualised EPS = ₹12.76
Commentary: Revenue is growing nicely, but EBITDA and PAT are growing like they just discovered steroids—legal ones. Operating margin has improved to 21%, which suggests operating leverage is kicking in. This is what diagnostics businesses dream of: machines running full, labs sweating, and finance teams smiling quietly.
But pause for a second—can this margin sustain when expansion accelerates? Or will costs creep
